Furthermore, overexpression of MCT1 was demonstrated to impair the efficacy of lenalidomide in human MM cells, both in vitro and in vivo, and high gene expression levels of SLC16A1 were associated with reduced PFS and OS in MM with lenalidomide-based maintenance therapy [28]. This evidence concerns the gene SLC16A1 and Miyoshi myopathy.